SCHEMBL27276337

SCHEMBL27276337

C=Cc1c(Oc2cccc(C(N)=S)c2)c(F)cc2[nH]ccc12

nearest known ligand 0.43

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
▸ ASH1L Q9NR48 11/20 0.43
▸ RHEB Q15382 4/20 0.33
▸ F10 P00742 3/20 0.33
▸ F2 P00734 1/20 0.33
▸ TRPA1 O75762 1/20 0.32
▸ MAPK1 P28482 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30285660 0.89 F10 (0.46) F10F2
SCHEMBL29336712 0.89 F10 (0.46) F10F2
SCHEMBL27282951 0.86 AKR1C3 (0.43) F10
SCHEMBL30840825 0.84 TRPA1 (0.33) ASH1LRHEBTRPA1
SCHEMBL30750124 0.82 F10 (0.32) RHEBF10F2TRPA1
SCHEMBL29237457 0.81 ASH1L (0.41) ASH1LRHEBF10F2
SCHEMBL30967824 0.81 ASH1L (0.41) ASH1LRHEBF10F2
SCHEMBL27275971 0.81 BRD4 (0.36) RHEBTRPA1
SCHEMBL31111109 0.78 TRPA1 (0.36) RHEBTRPA1
SCHEMBL30750345 0.77 BTK (0.37) RHEBTRPA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12624051-B2 Macrocyclic compounds, compositions, and methods of using thereof GENZYME CORPORATION (US) 2026-05-12 — — US disclosed
US-20260008786-A1 MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF SCHRODINGER, LLC 2026-01-08 — — US disclosed
US-20260008785-A1 MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF SCHRODINGER, LLC 2026-01-08 — — US disclosed
US-20250197422-A1 MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF SCHRODINGER, LLC 2025-06-19 — — US disclosed
WO-2024054840-A1 MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF SIONNA THERAPEUTICS (US) 2024-03-14 — — WO disclosed
WO-2024054851-A1 MACROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USING THEREOF SIONNA THERAPEUTICS (US) 2024-03-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12624051-B2 Macrocyclic compounds, compositions, and methods of using thereof CFTR, ABCC3, ABCD3 ASH1L 4687/4885RHEB 1600/4885F10 935/4885
US-20260008786-A1 MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF CFTR, ABCC3, ABCD3 ASH1L 4687/4885RHEB 1600/4885F10 935/4885
US-20260008785-A1 MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF CFTR, ABCC3, ABCD3 ASH1L 4710/4885RHEB 1622/4885F10 792/4885
US-20250197422-A1 MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF CFTR, ABCB1, PKD1 ASH1L 4724/4885RHEB 1111/4885F10 3549/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback